Slingshot members are tracking this event:
Data from First Set of 24-week Biopsies Expected Q2 or Q3 for UK Enrolled DMD patients in the Ongoing PhaseOut DMD trial
Do you think this event is important to the companies below? How will it affect their stock price?
"PhaseOut DMD, our Phase 2 proof of concept trial of ezutromid, is enrolling now in the UK and the US, and we are on track to report data from the first group of 24-week biopsies in the second or third quarter of 2017."
Slingshot Insights Explained
Jun 22, 2017
Related Keywords Dmd, Phase 2a Interim Data, Ezutromid